How to buy vTv Therapeutics stock

vTv Therapeutics Inc is a biotechnology business based in the US. vTv Therapeutics shares (VTVT) are listed on the NASDAQ and all prices are listed in US Dollars. vTv Therapeutics employs 25 staff and has a trailing 12-month revenue of around 0.00.

vTv Therapeutics share price

Use our graph to track the performance of VTVT stocks over time.

vTv Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$1.50 - $3.59
50-day moving average	$2.70
200-day moving average	$2.25
Wall St. target price	$6.75
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.56

Buy vTv Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy vTv Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of vTv Therapeutics Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

vTv Therapeutics financials

Revenue TTM	$6.4 million
Gross profit TTM	$-4,601,000
Return on assets TTM	-61.59%
Return on equity TTM	0%
Profit margin	-132.51%
Book value	$-1.67
Market capitalisation	$201.1 million

TTM: trailing 12 months

Shorting vTv Therapeutics shares

There are currently 2.2 million vTv Therapeutics shares held short by investors – that's known as vTv Therapeutics's "short interest". This figure is 4.5% down from 2.3 million last month.

There are a few different ways that this level of interest in shorting vTv Therapeutics shares can be evaluated.

vTv Therapeutics's "short interest ratio" (SIR)

vTv Therapeutics's "short interest ratio" (SIR) is the quantity of vTv Therapeutics shares currently shorted divided by the average quantity of vTv Therapeutics shares traded daily (recently around 1.2 million). vTv Therapeutics's SIR currently stands at 1.81. In other words for every 100,000 vTv Therapeutics shares traded daily on the market, roughly 1810 shares are currently held short.

However vTv Therapeutics's short interest can also be evaluated against the total number of vTv Therapeutics shares, or, against the total number of tradable vTv Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case vTv Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 vTv Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.1036% of the tradable shares (for every 100,000 tradable vTv Therapeutics shares, roughly 104 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against vTv Therapeutics.

Find out more about how you can short vTv Therapeutics stock.

vTv Therapeutics share dividends

We're not expecting vTv Therapeutics to pay a dividend over the next 12 months.

vTv Therapeutics share price volatility

Over the last 12 months, vTv Therapeutics's shares have ranged in value from as little as $1.5 up to $3.59. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while vTv Therapeutics's is -1.8152. This would suggest that vTv Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, vTv Therapeutics has bucked the trend.

vTv Therapeutics overview

vTv Therapeutics Inc. , a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases. It is also involved in the clinical development of other programs, including a small molecule GLP-1r agonist; the PDE4 inhibitor; HPP737, a PPAR-delta agonist; and an Nrf2 activator through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc.

Frequently asked questions

• What percentage of vTv Therapeutics is owned by institutions?

  Currently 4.366% of vTv Therapeutics shares are held by institutions.

• How many people work for vTv Therapeutics?

  Latest data suggests 25 work at vTv Therapeutics.

• When does the fiscal year end for vTv Therapeutics?

  vTv Therapeutics's fiscal year ends in December.

• Where is vTv Therapeutics based?

  vTv Therapeutics's address is: 3980 Premier Drive, High Point, NC, United States, 27265

• What is vTv Therapeutics's ISIN number?

  vTv Therapeutics's international securities identification number is: US9183851057

• What is vTv Therapeutics's CUSIP number?

  vTv Therapeutics's Committee on Uniform Securities Identification Procedures number is: 918385105